Author:
Rossato Luciana Grazziotin,Costa Vera Marisa,Vilas-Boas Vânia,de Lourdes Bastos Maria,Rolo Anabela,Palmeira Carlos,Remião Fernando
Publisher
Springer Science and Business Media LLC
Subject
Cardiology and Cardiovascular Medicine,Toxicology,Molecular Biology
Reference42 articles.
1. Seiter, K. (2005). Toxicity of the topoisomerase II inhibitors. Expert Opinion on Drug Safety, 4, 219–234.
2. Kingwell, E., Koch, M., Leung, B., Isserow, S., Geddes, J., Rieckmann, P., et al. (2010). Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MS. Neurology, 74, 1822–1826.
3. Khan, S. N., Lai, S. K., Kumar, P., & Khan, A. U. (2010). Effect of mitoxantrone on proliferation dynamics and cell cycle progression. Bioscience Reports, 30, 375–381.
4. Hajihassan, Z., & Rabbani-Chadegani, A. (2011). Interaction of mitoxantrone, as an anticancer drug, with chromatin proteins, core histones and H1, in solution. International Journal of Biological Macromolecules, 48, 87–92.
5. Alderton, P. M., Gross, J., & Green, M. D. (1992). Comparative study of doxorubicin, mitoxantrone, and epirubicin in combination with ICRF-187 (ADR-529) in a chronic cardiotoxicity animal model. Cancer Research, 52, 194–201.
Cited by
33 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献